Finance

Lists
Why is VYGR down 8,41%?
Dive Deeper
VYGR:NASDAQ
Voyager Therapeutics Inc
USD 2,45
-8,41%
(-0,22) 1D
USD 2,49
+1,63% (+0,040)
After hours
Closed: 2 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VYGR...
Open
USD 2,72
High
USD 2,73
Low
USD 2,42
Mkt. cap
150,68 m
Avg. vol.
498,26 k
Volume
1,16 m
52-wk high
USD 5,55
52-wk low
USD 2,42
EPS
-USD 1,81
Beta
1,29
Shares outstanding
61,62 m
No. of employees
141
Open
USD 2,72
High
USD 2,73
Low
USD 2,42
Mkt. cap
150,68 m
Avg. vol.
498,26 k
Volume
1,16 m
52-wk high
USD 5,55
52-wk low
USD 2,42
EPS
-USD 1,81
Beta
1,29
Shares outstanding
61,62 m
No. of employees
141
News stories
From web sources and news partners
About Voyager Therapeutics Inc
CEO-
Employees141
Founded2013
HeadquartersLexington, Massachusetts, Verenigde State van Amerika
Sector-
Websitevoyagertherapeutics.com
Analyst ratings
Based on 4 analysts giving stock ratings to VYGR in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for VYGR in the last 3 months.
Highest
Current USD 2,45
USD 25,00 (+920,41%)
Average
USD 15,00 (+512,24%)
Lowest
USD 8,00 (+226,53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
USD 25,00
+920,4%
09/21/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
USD 12,00
+389,8%
08/12/2026
Yun Zhong
Wedbush
Buy
Maintained
USD 8,00
+226,5%
08/07/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/06/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
USD 22,00
+798%
06/02/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
USD 18,00
+634,7%
05/08/2026
Samantha Semenkow
Citi
Buy
Reiterated
USD 11,00
+349%
03/23/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/17/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
USD 10,00
+308,2%
03/11/2026
Last report
06 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-USD 0,40 / -USD 0,51
+21,22%beat
Revenue / Est. (USD)
3,16 m / 4,56 m
-30,64%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
13,36 m
15,34 m
2,59 m
3,16 m
Cost of goods sold
35,87 m
33,55 m
24,60 m
22,04 m
Cost of revenue
35,87 m
33,55 m
24,60 m
22,04 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,09 m
8,22 m
8,26 m
7,52 m
Operating expense
8,09 m
8,22 m
8,26 m
7,52 m
Total operating expenses
43,96 m
41,77 m
32,86 m
29,56 m
Operating income
-30,59 m
-26,43 m
-30,27 m
-26,39 m
Other non operating income
400,00 k
404,00 k
435,00 k
411,00 k
EBT including unusual items
-27,81 m
-27,42 m
-27,92 m
-24,45 m
EBT excluding unusual items
-27,81 m
-23,92 m
-27,92 m
-24,45 m
Income tax expense
83,00 k
9,00 k
14,00 k
20,00 k
Effective tax rate
-0,30%
-0,03%
-0,05%
-0,08%
Other operating expenses
-
-
-
-
Net income
-27,89 m
-27,43 m
-27,94 m
-24,47 m
Net profit margin
-208,69%
-178,83%
-1 077,40%
-773,24%
Earnings per share
-0,47
-0,47
-0,47
-0,40
Interest and investment income
2,38 m
2,11 m
1,91 m
1,53 m
Interest expense
-
-
-
-
Net interest expenses
2,38 m
2,11 m
1,91 m
1,53 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-29,66 m
-25,38 m
-29,34 m
-25,48 m
Gain or loss from assets sale
-
62,00 k
-
105,00 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme